ストックスクリーナーアプリを入手
2.27
9.92%
-0.25
アフターアワーズ：
2.30
0.03
+1.32%
前日終値:
$2.52
開ける：
$2.4
24時間の取引高:
859.18K
Relative Volume:
1.04
時価総額：
$73.08M
収益：
-
当期純損益:
$-29.25M
株価収益率:
-1.914
EPS:
-1.186
ネットキャッシュフロー:
$-22.80M
1週間 パフォーマンス:
-39.63%
1か月 パフォーマンス:
-34.20%
6か月 パフォーマンス:
-44.90%
1年 パフォーマンス:
-58.20%
1日の値動き範囲:
$2.22
$2.43
1週間の範囲:
$2.22
$3.93
52週間の値動き範囲:
$2.22
$7.38
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
SGMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
2.27 | 73.08M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Holdings of Sagimet Biosciences Inc (SGMT) are aligned with the stars - Sete News
Virtu Financial LLC Sells 9,123 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus Price Target from Analysts - Defense World
HC Wainwright Issues Positive Estimate for SGMT Earnings - Defense World
Sagimet Biosciences (SGMT) Expected to Announce Earnings on Monday - Defense World
Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position - TipRanks
HC Wainwright Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Faces AI Integration Challenges: Security, Compliance, and Cost Risks Loom - TipRanks
Sagimet Biosciences Advances MASH Treatment with New Trials - TipRanks
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet’s FASN inhibitor cleared to enter clinic for acne - BioWorld MedTech
Sagimet Biosciences Inc. (SGMT) reports earnings - Quartz
Sagimet Biosciences Inc. SEC 10-K Report - TradingView
Sagimet's FDA Breakthrough Drug Enters Phase 3 Trials with $158M War Chest - StockTitan
Promising Developments in Sagimet Biosciences: IND Clearance for TVB-3567 and Ongoing Success of Denifanstat - TipRanks
Promising Pipeline and Positive Trial Data Support Buy Rating for Sagimet Biosciences - TipRanks
Sagimet Biosciences’ Strategic Expansion into Acne Treatment with Promising FASN Inhibitor TVB-3567 - TipRanks
Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials -March 11, 2025 at 10:46 am EDT - Marketscreener.com
Sagimet Biosciences receives FDA nod to begin testing its therapy for acne -March 11, 2025 at 09:38 am EDT - Marketscreener.com
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - SEC.gov
Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567 - TipRanks
Sagimet Biosciences Announces Clearance of IND for FASN - GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for ... - The Bakersfield Californian
FDA Clears Groundbreaking Acne Drug: Sagimet's New FASN Inhibitor Targets 50M Patient Market - StockTitan
Sagimet Biosciences’ Denifanstat Should Be Worth More Today (NASDAQ:SGMT) - Seeking Alpha
Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? - Insider Monkey
10 Best Get Rich Quick Stocks To Invest In - Insider Monkey
Brokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $23.00 - Defense World
10 Hot Penny Stocks to Buy Now - Insider Monkey
Unveiling Hidden Gems: The Hot Penny Stock You Might Be Missing - Reporteros del Sur -
Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now - Insider Monkey
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic ... - The Bakersfield Californian
Could This New MASH Drug Transform Liver Disease Treatment? Key Phase 2b Results Revealed - StockTitan
FY2024 Earnings Estimate for SGMT Issued By Leerink Partnrs - MarketBeat
Technical analysis of Sagimet Biosciences Inc (SGMT) stock chart patterns - US Post News
FY2024 Earnings Forecast for SGMT Issued By Leerink Partnrs - Defense World
Keeping an Eye on Sagimet Biosciences Inc (SGMT) After Insider Trading Activity - Knox Daily
Sagimet Biosciences Inc (NASDAQ:SGMT) Up 47.7% Since 52-Week Low; YTD Rose 1.56% – Here’s What You Need To Do – Marketing Sentinel - Marketing Sentinel
Equities Analysts Issue Forecasts for SGMT FY2029 Earnings - MarketBeat
Prepare Yourself for Liftoff: Sagimet Biosciences Inc (SGMT) - SETE News
Sagimet Biosciences Inc (SGMT)’s results reveal risk - US Post News
Analytical Overview: Sagimet Biosciences Inc (SGMT)’s Ratios Tell a Financial Story - The Dwinnex
US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks - Yahoo Finance
Buy Recommendation for Sagimet Biosciences: Denifanstat’s Unique Profile and Undervaluation Offer Compelling Investment Opportunity - TipRanks
What's Going On With Sagimet Biosciences Stock On Thursday? - MSN
JPMorgan Chase & Co. Boosts Stake in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):